ArticleFrontiers in immunology2026
Downregulated PLAU alleviates acute rejection after liver transplantation by targeting Ptgs2 in macrophages.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute rejection (AR) is a major determinant of poor prognosis after liver transplantation (LT), and macrophage M1-polarization can induce AR. Urokinase-type plasminogen activator (PLAU) has been implicated in the regulation of several liver diseases, but its role in AR remains unclear. Methods: In this study, through bioinformatics analysis and transcriptome sequencing, we find that PLAU and prostaglandin-endoperoxide synthase 2 (Ptgs2) can regulate macrophage polarization. To elucidate the effects of PLAU and Ptgs2 on AR, dynamic changes in PLAU and Ptgs2 expression are detected in both peripheral blood mononuclear cells (PBMCs) from clinical LT patients and hepatic macrophages from LT rats. Subsequently, to investigate the specific regulatory roles in macrophage M1-polarization and AR, downregulating PLAU and Ptgs2 rescue experiments are conducted Results: The expression of PLAU and Ptgs2 is increased in PBMCs from LT patients and in macrophages from LT rats, and most significantly on postoperative day 7. Downregulating PLAU alleviates AR and suppresses M1-polarization of macrophages. However, Ptgs2 rescue exacerbates AR and promotes M1-polarization of macrophages. The potential mechanism involves regulating the Protein kinase B/Nuclear factor kappa B (AKT/NF-κB) pathway. Conclusion: In summary, downregulated the PLAU/Ptgs2 axis can attenuate AR by regulating macrophage polarization, offering a promising new therapeutic target for preventing and treating AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.